These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

105 related articles for article (PubMed ID: 6689425)

  • 1. A dose and time response analysis of the treatment of Hodgkin's disease with MOPP chemotherapy.
    Carde P; MacKintosh FR; Rosenberg SA
    J Clin Oncol; 1983 Feb; 1(2):146-53. PubMed ID: 6689425
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Dose intensity of MOPP chemotherapy and survival in Hodgkin's disease.
    van Rijswijk RE; Haanen C; Dekker AW; de Meijer AJ; Verbeek J
    J Clin Oncol; 1989 Dec; 7(12):1776-82. PubMed ID: 2585019
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Can MOPP be replaced in the treatment of advanced Hodgkin's disease?
    Canellos GP
    Semin Oncol; 1990 Feb; 17(1 Suppl 2):2-6. PubMed ID: 1689509
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Predictive value of the early response to chemotherapy in high-risk stages II and III Hodgkin's disease.
    Levis A; Vitolo U; Ciocca Vasino MA; Cametti G; Urgesi A; Bertini M; Canta M; Monetti U; Bosio C; Jayme A
    Cancer; 1987 Oct; 60(8):1713-9. PubMed ID: 3651998
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Chemotherapy of advanced Hodgkin's disease with MOPP, ABVD, or MOPP alternating with ABVD.
    Canellos GP; Anderson JR; Propert KJ; Nissen N; Cooper MR; Henderson ES; Green MR; Gottlieb A; Peterson BA
    N Engl J Med; 1992 Nov; 327(21):1478-84. PubMed ID: 1383821
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Randomized study for the treatment of adult advanced Hodgkin's disease: mechlorethamine, vincristine, procarbazine, and prednisone (MOPP) versus lomustine, vinblastine, and prednisone.
    Liebman HA; Hum GJ; Sheehan WW; Ryden VM; Bateman JR
    Cancer Treat Rep; 1983 May; 67(5):413-9. PubMed ID: 6342771
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Treatment of advanced-stage Hodgkin's disease: alternating noncrossresistant MOPP/CABS is not superior to MOPP.
    Longo DL; Duffey PL; DeVita VT; Wiernik PH; Hubbard SM; Phares JC; Bastian AW; Jaffe ES; Young RC
    J Clin Oncol; 1991 Aug; 9(8):1409-20. PubMed ID: 1712836
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Randomized study for the treatment of advanced Hodgkin's disease: MOPP vs. LOPP.
    Avilés A; Díaz-Maqueo JC; García EL; Torras V; López-Vancell D
    Arch Invest Med (Mex); 1991; 22(1):45-50. PubMed ID: 1819976
    [TBL] [Abstract][Full Text] [Related]  

  • 9. High-dose chemotherapy with autologous bone marrow transplantation in 50 advanced resistant Hodgkin's disease patients: an Italian study group report.
    Carella AM; Congiu AM; Gaozza E; Mazza P; Ricci P; Visani G; Meloni G; Cimino G; Mangoni L; Coser P
    J Clin Oncol; 1988 Sep; 6(9):1411-6. PubMed ID: 2458439
    [TBL] [Abstract][Full Text] [Related]  

  • 10. A randomized study in stage IIIB and IV Hodgkin's disease comparing eight courses of MOPP versus an alteration of MOPP with ABVD: a European Organization for Research and Treatment of Cancer Lymphoma Cooperative Group and Groupe Pierre-et-Marie-Curie controlled clinical trial.
    Somers R; Carde P; Henry-Amar M; Tarayre M; Thomas J; Hagenbeek A; Monconduit M; de Pauw BE; Breed WP; Verdonck L
    J Clin Oncol; 1994 Feb; 12(2):279-87. PubMed ID: 7509381
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Treatment of advanced Hodgkin's disease with chemotherapy--comparison of MOPP/ABV hybrid regimen with alternating courses of MOPP and ABVD: a report from the National Cancer Institute of Canada clinical trials group.
    Connors JM; Klimo P; Adams G; Burns BF; Cooper I; Meyer RM; O'Reilly SE; Pater J; Quirt I; Sadura A; Shustik C; Skillings J; Sutcliffe S; Verma S; Yoshida S; Zee B
    J Clin Oncol; 1997 Apr; 15(4):1638-45. PubMed ID: 9193364
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Randomized study of intensive MOPP-ABVD with or without low-dose total-nodal radiation therapy in the treatment of stages IIB, IIIA2, IIIB, and IV Hodgkin's disease in pediatric patients: a Pediatric Oncology Group study.
    Weiner MA; Leventhal B; Brecher ML; Marcus RB; Cantor A; Gieser PW; Ternberg JL; Behm FG; Wharam MD; Chauvenet AR
    J Clin Oncol; 1997 Aug; 15(8):2769-79. PubMed ID: 9256118
    [TBL] [Abstract][Full Text] [Related]  

  • 13. The role of dose and rate of administration of MOPP drugs in 97 retrospective Hodgkin's patients.
    Gobbi PG; Cavalli C; Rossi A; Bertoloni D; Galeone F; Pieresca C; Grignani E
    Haematologica; 1987; 72(6):523-8. PubMed ID: 3126109
    [No Abstract]   [Full Text] [Related]  

  • 14. Treatment of Hodgkin's disease with MOPP chemotherapy: effect of dose and schedule modification on treatment outcome.
    Bezwoda WR; Dansey R; Bezwoda MA
    Oncology; 1990; 47(1):29-36. PubMed ID: 1689018
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Nitrogen mustard, vincristine, procarbazine, and prednisolone for relapse after radiation in Hodgkin's disease. An analysis of long-term follow-up.
    Olver IN; Wolf MM; Cruickshank D; Worotniuk V; Ding JC; Cooper IA; Matthews JP
    Cancer; 1988 Jul; 62(2):233-9. PubMed ID: 3383124
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Two different schedules for integrating filgrastim as adjuvant therapy in the treatment of patients with advanced stage Hodgkin's lymphoma receiving MOPP/ABV hybrid chemotherapy.
    Cantin G; L'Espérance B; Yelle L; Desjardins L; Couture F; Bergeron M; Lacroix L; Dufresne J; Bélanger D; Ouellet PA; Hewitt LA; Pirc L; Gyger M
    Cancer Chemother Pharmacol; 1999; 43(6):503-6. PubMed ID: 10321511
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Long-term follow-up with ABDIC salvage chemotherapy of MOPP-resistant Hodgkin's disease.
    Tannir N; Hagemeister F; Velasquez W; Cabanillas F
    J Clin Oncol; 1983 Jul; 1(7):432-9. PubMed ID: 6199478
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Twenty years of MOPP therapy for Hodgkin's disease.
    Longo DL; Young RC; Wesley M; Hubbard SM; Duffey PL; Jaffe ES; DeVita VT
    J Clin Oncol; 1986 Sep; 4(9):1295-306. PubMed ID: 3528400
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Chemotherapy plus involved-field radiation in early-stage Hodgkin's disease.
    Fermé C; Eghbali H; Meerwaldt JH; Rieux C; Bosq J; Berger F; Girinsky T; Brice P; van't Veer MB; Walewski JA; Lederlin P; Tirelli U; Carde P; Van den Neste E; Gyan E; Monconduit M; Diviné M; Raemaekers JM; Salles G; Noordijk EM; Creemers GJ; Gabarre J; Hagenbeek A; Reman O; Blanc M; Thomas J; Vié B; Kluin-Nelemans JC; Viseu F; Baars JW; Poortmans P; Lugtenburg PJ; Carrie C; Jaubert J; Henry-Amar M;
    N Engl J Med; 2007 Nov; 357(19):1916-27. PubMed ID: 17989384
    [TBL] [Abstract][Full Text] [Related]  

  • 20. [Chemotherapy of advanced lymphogranulomatosis. Results of MOPP/COPP treatment at the West German Tumor Center, Essen].
    Höffken K; Ippisch A; Pfeiffer R; Becher R; Seeber S; Schmidt CG
    Dtsch Med Wochenschr; 1985 Apr; 110(16):618-23. PubMed ID: 3838719
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 6.